{
  "id": "33a72534689009a5",
  "title": "Rybrevant Faspro FDA - Approved as First Sub - Q Therapy for EGFR NSCLC",
  "description": "20251218T020000Z",
  "content": "",
  "source": "curetoday.com",
  "source_url": "https://www.curetoday.com/view/rybrevant-faspro-fda-approved-as-first-sub-q-therapy-for-egfr-nsclc",
  "published_at": "20251218T020000Z",
  "fetched_at": "2025-12-19T00:23:08.544189+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.curetoday.com/view/rybrevant-faspro-fda-approved-as-first-sub-q-therapy-for-egfr-nsclc",
    "url_mobile": "",
    "title": "Rybrevant Faspro FDA - Approved as First Sub - Q Therapy for EGFR NSCLC",
    "seendate": "20251218T020000Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/curetoday/be808240055c77ced9ad871964c58e81f2e749d0-1280x720.jpg",
    "domain": "curetoday.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}